Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
European Commission Approves Rasonque for Metastatic Pancreatic Cancer Treatment

European Commission Approves Rasonque for Metastatic Pancreatic Cancer Treatment

November 18, 2026 Health Desk Health

“For decades, physicians treating metastatic pancreatic cancer have had limited options beyond cytotoxic chemotherapy,” said Thomas Seufferlein, medical director of the Clinic for Internal Medicine I at Ulm University Hospital.

The European Commission has now approved Rasonque (daraxonrasib), a once-daily oral tablet from Revolution Medicines, for adults with metastatic pancreatic adenocarcinoma who have already received at least one systemic therapy.

Key Clinical Takeaways:

  • The European Commission granted marketing authorisation for daraxonrasib on November 16, 2026, covering all EU member states plus Liechtenstein, Iceland and Norway.
  • In the Phase III RASolute 302 trial, patients on the drug lived on average for a further 12.4 months versus 6.7 months on chemotherapy.
  • The approval applies regardless of whether a tumour carries an identified RAS mutation, though national pricing and reimbursement processes will decide when patients can actually receive it.

EC approval covers most EU nations

The authorisation permits use of the drug in patients with or without an identified RAS tumour mutation, a point Revolution Medicines stressed in its announcement, as Pharmaceutical Technology reported. It applies across all 27 EU member states and the European Economic Area nations of Liechtenstein, Iceland and Norway. Switzerland and the UK fall outside it, since both run independent regulatory frameworks.

The European Commission has granted marketing authorization for our oral RAS(ON) multi-selective inhibitor for previously treated metastatic pancreatic cancer. Read more: https://t.co/QLZ5HmQyFK #ForMediaOnly pic.twitter.com/IuCvpv6YBc

— Post by @RevMedicines on X

Availability is not immediate. Patient access will vary by jurisdiction while national pricing, health-technology assessment and reimbursement procedures are completed. The company says it is working with national assessment bodies to speed that up, according to Oncodaily – Oncology News, Insights, Stories.

The trial behind the decision: RASolute 302

The EC’s authorisation rests on the global Phase III RASolute 302 registrational trial (NCT06625320), registered on ClinicalTrials.gov and published in The New England Journal of Medicine. The data was also presented at the 2026 American Society of Clinical Oncology Annual Meeting.

European Commission
Photo: Oncodaily

RASolute 302 enrolled 500 patients with previously treated metastatic pancreatic adenocarcinoma. It compared a daily 300mg dose of daraxonrasib monotherapy against an investigator’s choice of four cytotoxic chemotherapy regimens. The study met all primary and key secondary endpoints, both in the overall intent-to-treat group and in patients harbouring RAS G12 mutations.

The survival figures carry the comparison patients and their oncologists will weigh. Patients receiving daraxonrasib lived on average a further 12.4 months, against 6.7 months for those on chemotherapy. The drug acts on a protein altered in roughly 90 per cent of pancreatic cancer cases, driving uncontrolled cell multiplication.

Instagram

Safety profile: what the prescribing information shows

Detailed safety reporting has come from Oncodaily, which cited the US prescribing information. Dermatologic and soft tissue toxicity occurred in 86 per cent of patients, with grade 3 toxicity at 10 per cent. Manifestations included rash, pruritus, paronychia, dry skin and skin fissures.

“The prescribing information outlines treatment interruption, dose reduction, or permanent discontinuation for certain adverse reactions depending on severity.”

A rare RAS-targeted option in a hard-to-treat cancer

Daraxonrasib is a RAS(ON) multi-selective, noncovalent, tri-complex inhibitor. Until now, treatment choices beyond cytotoxic chemotherapy in this setting have been narrow, which is precisely why Seufferlein framed the approval as answering “the urgent need for new therapeutic approaches.”

🚨Breaking🚨 European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancerhttps://t.co/UURiEo0LcP Learn more 👉 https://t.co/XtygaGCht0#LARVOL #CancerResearch #CancerData #Oncology… pic.twitter.com/myo4n47XcY

— Post by @Larvol on X

The epidemiological backdrop gives the approval weight. Pancreatic cancer is frequently detected late, often only after spread, because early disease causes no symptoms beyond non-specific ones such as weight loss or upper abdominal and back pain. One in ten patients survives five years after diagnosis, according to cancer registry data from the Robert Koch Institute, the German government health agency. The disease usually occurs in people aged over 70.

For patients already in treatment, the approval’s practical meaning depends on local reimbursement timelines. Discussing eligibility for a targeted agent of this kind is a decision for the treating medical oncology team, who can assess whether a patient’s prior systemic therapy history and tumour profile fit the approved indication.

$RVMD European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer More Info: https://t.co/iFDYlKNirR pic.twitter.com/ZsVf9upDEt

— Post by @OzmosiHealth on X

How the regulator moved: expedited review

The assessment ran under an expedited phased review within the EMA’s Cancer Medicines Pathfinder project, reflecting high unmet medical need, Pharmaceutical Technology reported.

The company’s next moves, in Europe and beyond

Rasonque already holds approval from the US Food and Drug Administration for adults with metastatic disease who have received prior systemic therapy or cannot receive multiagent regimens.

The pipeline extends beyond pancreas. Revolution Medicines is evaluating it in global Phase III registrational trials for metastatic RAS-mutant non-small cell lung cancer and pancreatic cancer, and in August signed a multi-part collaboration with BeOne Medicines to develop and commercialise targeted oncology therapies.

The next dates on the record are national: pricing, health-technology assessment and reimbursement decisions in individual EU countries will determine when eligible patients can actually be prescribed daraxonrasib, with the company aiming to support timely access across the region.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

More on this

  • Hungary’s Foreign Ministry Paid Orbán Millions for Football Trips
  • Alyssa Farah Griffin Compares System Failures to Eerie Feeling Before COVID Pandemic
  • Pope Leo XIV Cleared for South America Tour After Lung Cancer Surgery (newsdirectory3.com)

Related

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service